As a pre‐planned exploratory analysis to evaluate the impact of ivosidenib in the treatment strategy of CCA, we compared the second‐line outcomes of the study cohort with those of a previously published historical cohort of patients affected by advanced IDH1 mutant CCA treated with second‐line FOLFOX/CAPOX. Here, IDH1 is linked to cholangiocarcinoma.